KLOW
Multi-Peptide Research Blend - Multi-peptide tissue-repair blend: KPV, GHK-Cu, TB-500 & BPC-157.
A comprehensive multi-peptide blend co-formulating several regenerative-research compounds, prepared for laboratories studying combined tissue-repair and barrier-function protocols.
The KLOW formulation is aimed at laboratories that want to study several regenerative mechanisms in a single, consistent preparation rather than reconstituting four compounds separately. It is best understood as a convenience blend for combination protocols, with the caveat that attributing any single effect to one component is not possible from the blend alone.
KLOW specifications
- Molecular formula
- Co-formulated blend
- Sequence
- KPV + Larazotide + GHK-Cu + BPC-157/TB-500
- Residues
- KPV + GHK-Cu + BPC-157 + TB-500
- Presentation
- Blue lyophilized powder
- Documented purity
- 99.71% by HPLC
- Available sizes
- 80mg ($90)
- Archived COA lots
- 10
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Combined barrier & repair - Formulated for study of overlapping repair, anti-inflammatory and matrix pathways.
Reported mechanisms in the literature
- Combined barrier & repair - Formulated for study of overlapping repair, anti-inflammatory and matrix pathways across four regenerative-research compounds in a single protocol. (Combination research)
- Barrier-function research - Investigated for the interaction between anti-inflammatory tripeptide signaling and copper-peptide matrix remodeling alongside repair peptides. (Preclinical literature)
What KLOW is researched for
- Combined repair - Studied as a multi-peptide preparation for overlapping tissue-repair and barrier pathways. (Combination research)
- Skin & matrix - Investigated for combined copper-peptide and repair-peptide effects on skin models. (Preclinical literature)
KLOW certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| KLOW-101926-80 | 22 Oct 2026 | 80mg | ILS Laboratories | 99.53% | Confirmed (HPLC retention time) | COA PDF |
| 3SUW55 | 3 Oct 2026 | 80mg | Freedom Diagnostics | 99.86% | Confirmed (LC-MS/MS) | COA PDF |
| 2S7TX2 | 25 Sep 2026 | 80mg | Freedom Diagnostics | 99.96% | Confirmed (LC-MS/MS) | COA PDF |
| RXY8XM | 21 Aug 2026 | 80mg | Accurate Test Labs | 99.77% | Confirmed (LC-MS/MS) | COA PDF |
| S7UDXN | 11 Aug 2026 | 80mg | Accurate Test Labs | 99.93% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605270308 | 27 May 2026 | 80mg | Freedom Diagnostics | 99.76% | Confirmed (LC-MS/MS) | COA PDF |
| KLOW-032026-4 | 21 May 2026 | 80mg | Freedom Diagnostics | 99.75% | Confirmed (LC-MS/MS) | COA PDF |
| KLOW-032026-1 | 1 May 2026 | 80mg | Freedom Diagnostics | 99.61% | Confirmed (LC-MS/MS) | COA PDF |
| See certificate | 24 Mar 2026 | Freedom Diagnostics | 99.61% | Confirmed (LC-MS/MS) | COA PDF | |
| See certificate | 10 Mar 2026 | Freedom Diagnostics | 99.75% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on KLOW
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
KLOW frequently asked questions
What is in the KLOW blend?
A co-formulation of KPV, GHK-Cu, BPC-157 and TB-500, prepared for laboratories studying combined tissue-repair and barrier-function protocols.
Is the blend approved for human use?
No. None of the components is approved for human use, and the blend is a research material only.
How is it documented?
The vial ships with a Certificate of Analysis for the combined lot.
Documented to 99.71% purity by HPLC · third-party COA every lot · from $90 · For laboratory research use only.
Related Regenerative & Repair compounds
- BPC-157 - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signaling.
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.
- BPC-157 / TB-500 / KPV - BPC-157, TB-500 and KPV co-formulated in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodeling research.
- KPV - α-MSH C-terminal fragment studied for inflammatory signaling.